BioDlink International Company Limited (HKG:1875)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
4.880
+0.300 (6.55%)
Apr 29, 2026, 4:08 PM HKT
148.98%
Market Cap 3.77B
Revenue (ttm) 831.99M
Net Income (ttm) -111.69M
Shares Out 772.79M
EPS (ttm) -0.15
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 4,129,600
Average Volume 1,906,370
Open 4.710
Previous Close 4.580
Day's Range 4.700 - 5.020
52-Week Range 1.700 - 5.870
Beta -0.06
RSI 54.75
Earnings Date Mar 18, 2026

About HKG:1875

BioDlink International Company Limited, an investment holding company, engages in the research and development, manufacturing, and marketing of anti-tumor drugs in Mainland China and internationally. The company offers Pusintin, a bevacizumab injection to treat advanced, metastatic or recurrent non-squamous non-small cell lung cancer; metastatic colorectal cancer; recurrent glioblastoma multiforme; epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer; and cervical cancer. It also provides Tazian, a temozolomide capsule... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2009
Employees 613
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 1875
Full Company Profile

Financial Performance

Financial numbers in CNY Financial Statements

News

There is no news available yet.